SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Alzheimer's Disease and Other Dementias®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chow, T. W.
Right arrow Articles by Mendez, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chow, T. W.
Right arrow Articles by Mendez, M. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration

Tiffany W. Chow, MD

University of Southern California at Los Angeles; Rancho Los Amigos/USC Frontotemporal Dementia Clinic and Research Program, Downey, California.

Mario F. Mendez, MD, PhD

Department of Neurology, University of California at Los Angeles.

This review of pharmacotherapy for frontotemporal lobar degeneration describes the chemical rationale for agents used and reports observed responses to psychotropic medications. Paroxetine addressed anxiety and repetitive, ritualistic behaviors. Depression was resistant to treatment. Valproic acid and quetiapine calmed agitated subjects without exacerbating Parkinsonism. Donepezil has not emerged as a beneficial medication for this group of subjects. Behavioral disturbances can be alleviated pharmacologically, but further research might determine guidelines for management of this non-Alzheimer's dementia syndrome that could decrease the frequency of adverse drug events.

Key Words: frontotemporal dementia • pharmacotherapy • valproic acid • paroxetine • quetiapine • donepezil

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 17, No. 5, 267-272 (2002)
DOI: 10.1177/153331750201700504
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
M. F. Mendez, E. C. Lauterbach, S. M. Sampson, and ANPA Committee on Research
An Evidence-Based Review of the Psychopathology of Frontotemporal Dementia: A Report of the ANPA Committee on Research
J Neuropsychiatry Clin Neurosci, May 1, 2008; 20(2): 130 - 149.
[Abstract] [Full Text] [PDF]


Advertisement